WHO warned about the continued anti-viral drug remadevivir

Corona virus continues to wreak havoc worldwide. Scientists around the world are developing vaccines to deal with this global epidemic. Corona virus vaccine testing is in the final stages in many countries. Meanwhile, the World Health Organization (WHO) on Friday warned about the continued anti-viral drug remadesivir used to treat the corona virus. WHO stated that remadesivir should not be used for the treatment of corona patients. There is no evidence of corona infected patients recovering from this.

WHO  warned about the continued anti-viral drug remadevivir
WHO warned about the continued anti-viral drug remadevivir

WHO Guideline Development Group (GDG) international experts said, “There is no evidence from the present data that remadesivir patients are recovering from this drug.” The latest guidelines state that the panel has not found any such evidence of remadesivir, which suggests that the drug may have reduced the death rate or that patients may have needed mechanical ventilation after its use. Remadesivir was first created for the Ebola virus, but the drug could not achieve much success.


Subsequently, ten of the drug also began to be used on corona virus patients. Some trials also led to better results. This led to the use of the drug remadesivir to cure corona patients in many countries around the world. It is currently being used only in emergency cases in India and has not received full clearance.


A WHO trial last month showed that the drug had little or no effect on the corona patients. The WHO’s latest guidelines are a major setback for the pharmaceutical company. The WHO’s Guideline Development Group panel said its recommendation is based on an evidence review, which includes data from more than 7,000 patients on trial.

However, the US, European Union and other countries have approved the temporary use of ramdesivir. In early research, this step was taken with Remdesivir after some patients found it helpful to reduce the recovery time.

Leave a Reply

Your email address will not be published. Required fields are marked *